Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 15

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
 extended transition
period, difficult or impossible because of the potential differences in accounting standards used.

Use
of Estimates

The
preparation of financial statement in conformity with GAAP requires the Company’s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statement.

Making
estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of
a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating
its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ
significantly from those estimates.

8

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

Cash
and Cash Equivalents

The
Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
The Company had $717 and $1,351 in cash and no cash equivalents as of September 30, 2025 and December 31, 2024, respectively.

Cash
and Investments Held in Trust Account

As of September
30, 2025, cash and investments held in the Trust Account were held in money market funds which invest in U.S. Treasury securities. All
of the Company’s cash and investments held in the Trust Account are classified as trading securities. Trading securities are presented
on the unaudited balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair
value of cash and investments held in the Trust Account are included in interest earned on cash and investments held in Trust Account
in the accompanying unaudited statement of operations. The estimated fair values of cash and investments held in Trust Account are determined
using available market information. Fair values of these investments are determined by Level 1 inputs utilizing quoted prices (unadjusted)
in active markets for identical assets.

Offering
Costs

The
Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A —
“Expenses of Offering”. Offering costs consist principally of professional and registration fees that are related to the
Initial Public Offering. FASB ASC 470-20,